The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

A surge in deals and financings had the industry abuzz heading into this year’s J.P. Morgan Healthcare Conference. But some ...

The first day of San Francisco’s J.P. Morgan Healthcare Conference, usually punctuated by major announcements of mergers and ...

The financing, which will back a novel type of cancer drug, is the largest of a series of startup fundings announced at the ...

After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...

Medpace HoldingsMEDP is Tuesday's IBD Stock Of The Day. Shares are testing an early entry as the biotech funding environment ...

Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Boston CEOs point to a rise in ...

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

Danish biotech startup Bactolife has secured more than €30 million in a Series B funding round, marking a significant ...

TheraVectys SA is weighing Hong Kong for its public market debut as biotech listings rebound and Asia’s funding role grows.